ÂÜÀòÂÒÂ×

As President and Chief Scientific Officer of CYP450-GP, Dr. Lasker supervises the production and characterization of the firm’s collection of inhibitory human P450 antibodies and purified human P450 enzymes. Previously, Dr. Lasker held research faculty posts at the Mount Sinai School of Medicine (New York, NY) and the Jurist Institute for Research, Hackensack University Medical Center/University of Medicine & Dentistry of New Jersey (Hackensack and Newark, NJ). More recently, he served as Director of Laboratory Operations at Puracyp Inc. (Carlsbad, CA), where he managed studies that examined the capacity of new molecular entities to elicit drug-drug interactions. Dr. Lasker has served as a member of Center for Scientific

Review grant study sections, and is also a reviewer for the Journal of Pharmacology & Experimental Therapeutics, Drug Metabolism & Disposition and Molecular Pharmacology. He received his Ph.D. in Pharmacology from Duke University, and then completed a postdoctoral fellowship in the Department of Biochemistry & Drug Metabolism, Hoffmann-LaRoche Inc. Dr. Lasker has dedicated nearly his entire professional career to investigating human P450 catalytic function upon the isolation of these enzymes from liver or heterologous expression systems. An important facet of this work has involved using specific inhibitory antibodies to establish whether the metabolic properties of a given purified and reconstituted P450 enzyme are comparable to those same properties in intact liver microsomes.